Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGSNASDAQ:ATHENASDAQ:BMRANASDAQ:ESLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$7.20+19.0%$5.39$3.76▼$46.80$44.02M2.69204,159 shs257,239 shsATHEAlterity Therapeutics$4.73-1.7%$3.76$1.00▼$5.87$41.94M0.8143,408 shs18,212 shsBMRABiomerica$3.38+4.3%$3.65$1.93▼$10.16$8.25M0.34277,934 shs8,780 shsESLAEstrella Immunopharma$1.07+0.5%$0.96$0.63▼$3.23$38.52M0.41125,419 shs70,488 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics+19.01%+33.58%+65.14%-44.36%-51.96%ATHEAlterity Therapeutics-2.07%+6.05%+19.75%+27.15%+155.68%BMRABiomerica+4.32%+10.82%-2.45%-34.39%-24.04%ESLAEstrella Immunopharma+0.48%+9.80%-4.90%+7.80%+14.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALGSAligos Therapeutics4.1014 of 5 stars3.54.00.04.80.61.70.6ATHEAlterity Therapeutics1.7234 of 5 stars3.33.00.00.01.51.70.0BMRABiomerica0.9539 of 5 stars0.05.00.00.02.70.80.0ESLAEstrella Immunopharma2.593 of 5 stars3.55.00.00.01.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 3.00Buy$70.00872.22% UpsideATHEAlterity Therapeutics 2.50Moderate Buy$12.00153.70% UpsideBMRABiomerica 0.00N/AN/AN/AESLAEstrella Immunopharma 3.00Buy$16.001,402.21% UpsideCurrent Analyst Ratings BreakdownLatest BMRA, ALGS, ESLA, and ATHE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/31/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.003/11/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$3.27M13.46N/AN/A$30.65 per share0.23ATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/ABMRABiomerica$5.68M1.52N/AN/A$0.39 per share8.67ESLAEstrella ImmunopharmaN/AN/AN/AN/A$0.12 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$87.68M-$17.51N/AN/AN/A-1,283.19%-114.34%-64.58%8/5/2025 (Estimated)ATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/A8/4/2025 (Estimated)BMRABiomerica-$5.98M-$2.32N/A∞N/A-100.52%-90.19%-64.54%8/26/2025 (Estimated)ESLAEstrella Immunopharma-$7.31M-$0.26N/A∞N/AN/A-195.77%-157.28%N/ALatest BMRA, ALGS, ESLA, and ATHE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025ALGSAligos Therapeutics-$2.80-$2.11+$0.69-$2.11$0.33 million$0.31 million4/14/2025Q3 2025BMRABiomericaN/A-$0.48N/A-$0.06N/A$1.12 million3/10/2025Q4 2024ALGSAligos Therapeutics-$2.63-$13.08-$10.45-$13.08$0.43 million$0.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/ABMRABiomericaN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A3.813.81ATHEAlterity TherapeuticsN/A3.543.54BMRABiomericaN/A3.172.22ESLAEstrella ImmunopharmaN/A0.750.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%ATHEAlterity Therapeutics2.14%BMRABiomerica22.28%ESLAEstrella Immunopharma0.35%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics4.80%ATHEAlterity Therapeutics38.80%BMRABiomerica15.00%ESLAEstrella Immunopharma55.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.11 million3.27 millionNo DataATHEAlterity Therapeutics108.87 million5.35 millionNot OptionableBMRABiomerica602.55 million15.59 millionOptionableESLAEstrella ImmunopharmaN/A36.17 million16.24 millionNot OptionableBMRA, ALGS, ESLA, and ATHE HeadlinesRecent News About These CompaniesEstrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaJune 5 at 5:14 PM | finance.yahoo.comEstrella Immunopharma to sell 2.333M shares at $1.50 in private placementJune 4 at 5:30 AM | msn.comEstrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity FinancingJune 4 at 5:30 AM | finance.yahoo.comD. Boral Capital Reaffirms "Buy" Rating for Estrella Immunopharma (NASDAQ:ESLA)May 31, 2025 | americanbankingnews.comESLA Estrella Immunopharma, Inc.May 30, 2025 | seekingalpha.comEstrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II TrialMay 30, 2025 | msn.comEstrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s LymphomasMay 29, 2025 | finance.yahoo.comEstrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's LymphomasMay 29, 2025 | businesswire.comEstrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital PartnersMarch 5, 2025 | finance.yahoo.comEstrella Immunopharma completes first dose cohort in STARLIGHT trialFebruary 21, 2025 | markets.businessinsider.comEstrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose CohortFebruary 21, 2025 | businesswire.comEstrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral CapitalFebruary 19, 2025 | businesswire.comD. Boral Capital Initiates Coverage of Estrella Immunopharma (ESLA) with Buy RecommendationFebruary 19, 2025 | msn.comSpotlight On US Penny Stocks: Estrella Immunopharma And Two Others To ConsiderNovember 19, 2024 | uk.finance.yahoo.comEstrella Immunopharma (NASDAQ:ESLA) Stock, Short Interest ReportOctober 11, 2024 | benzinga.comEstrella Immunopharma (NASDAQ:ESLA) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comEstrella Immunopharma Inc (ESLA) Stock: Unveiling Its Hidden StrengthsSeptember 30, 2024 | bovnews.comEstrella Immunopharma Shares Rise on Lymphoma Patient's Treatment ResponseSeptember 28, 2024 | marketwatch.comEstrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cellsSeptember 27, 2024 | finance.yahoo.comEstrella Immunopharma, Inc. (ESLAW)August 24, 2024 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesUber Stock Ready to Ride Higher on Waymo PartnershipBy Gabriel Osorio-Mazilli | May 28, 2025View Uber Stock Ready to Ride Higher on Waymo PartnershipTesla: Why Analysts Think It Could Jump Another 47%By Sam Quirke | May 27, 2025View Tesla: Why Analysts Think It Could Jump Another 47%Tesla: Get Ready To See It Trading Above $400 AgainBy Sam Quirke | May 14, 2025View Tesla: Get Ready To See It Trading Above $400 AgainMagnificent 7 Stocks Shift Toward Stability and Selective GrowthBy Gabriel Osorio-Mazilli | May 19, 2025View Magnificent 7 Stocks Shift Toward Stability and Selective GrowthAlphabet Stock Lags—But Waymo May Be Its Hidden DriverBy Gabriel Osorio-Mazilli | May 25, 2025View Alphabet Stock Lags—But Waymo May Be Its Hidden DriverBMRA, ALGS, ESLA, and ATHE Company DescriptionsAligos Therapeutics NASDAQ:ALGS$7.20 +1.15 (+19.01%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$7.33 +0.13 (+1.81%) As of 06/6/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Alterity Therapeutics NASDAQ:ATHE$4.73 -0.08 (-1.66%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$4.67 -0.06 (-1.27%) As of 06/6/2025 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Biomerica NASDAQ:BMRA$3.38 +0.14 (+4.32%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$3.25 -0.13 (-3.85%) As of 06/6/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Estrella Immunopharma NASDAQ:ESLA$1.07 +0.01 (+0.48%) Closing price 06/6/2025 03:58 PM EasternExtended Trading$1.06 0.00 (-0.01%) As of 06/6/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
